CRISPR Therapeutics Past Earnings Performance
Past criteria checks 0/6
CRISPR Therapeutics's earnings have been declining at an average annual rate of -22.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been growing at an average rate of 13.1% per year.
Key information
-22.2%
Earnings growth rate
-15.8%
EPS growth rate
| Biotechs Industry Growth | 18.9% |
| Revenue growth rate | 13.1% |
| Return on equity | -8.2% |
| Net Margin | -41.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How CRISPR Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 371 | -154 | 76 | 0 |
| 30 Sep 23 | 170 | -354 | 81 | 0 |
| 30 Jun 23 | 170 | -416 | 90 | 0 |
| 31 Mar 23 | 100 | -524 | 97 | 0 |
| 31 Dec 22 | 1 | -650 | 102 | 0 |
| 30 Sep 22 | 14 | -681 | 105 | 0 |
| 30 Jun 22 | 15 | -633 | 102 | 0 |
| 31 Mar 22 | 915 | 312 | 103 | 0 |
| 31 Dec 21 | 915 | 378 | 100 | 0 |
| 30 Sep 21 | 902 | 412 | 102 | 0 |
| 30 Jun 21 | 902 | 447 | 100 | 0 |
| 31 Mar 21 | 1 | -392 | 93 | 0 |
| 31 Dec 20 | 1 | -349 | 86 | 0 |
| 30 Sep 20 | 77 | -211 | 80 | 0 |
| 30 Jun 20 | 289 | 20 | 74 | 0 |
| 31 Mar 20 | 289 | 46 | 68 | -5 |
| 31 Dec 19 | 290 | 67 | 63 | 0 |
| 30 Sep 19 | 213 | -11 | 63 | 0 |
| 30 Jun 19 | 1 | -200 | 57 | 0 |
| 31 Mar 19 | 2 | -185 | 54 | 5 |
| 31 Dec 18 | 3 | -165 | 48 | 0 |
| 30 Sep 18 | 35 | -117 | 43 | 0 |
| 30 Jun 18 | 37 | -91 | 41 | 0 |
| 31 Mar 18 | 40 | -75 | 36 | 0 |
| 31 Dec 17 | 41 | -68 | 36 | 0 |
| 30 Sep 17 | 11 | -51 | 35 | 0 |
| 30 Jun 17 | 10 | -41 | 31 | 0 |
| 31 Mar 17 | 7 | -36 | 32 | 0 |
| 31 Dec 16 | 5 | -23 | 31 | 0 |
| 30 Sep 16 | 3 | -53 | 25 | 0 |
| 30 Jun 16 | 2 | -44 | 24 | 0 |
| 31 Mar 16 | 1 | -31 | 17 | 0 |
| 31 Dec 15 | 0 | -26 | 13 | 0 |
Quality Earnings: 1CG is currently unprofitable.
Growing Profit Margin: 1CG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1CG is unprofitable, and losses have increased over the past 5 years at a rate of 22.2% per year.
Accelerating Growth: Unable to compare 1CG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1CG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 1CG has a negative Return on Equity (-8.16%), as it is currently unprofitable.